<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57058">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363270</url>
  </required_header>
  <id_info>
    <org_study_id>2014-10-08-MMC</org_study_id>
    <nct_id>NCT02363270</nct_id>
  </id_info>
  <brief_title>Ketamine: Comparison of IV Push vs. IV Drip</brief_title>
  <official_title>Comparison of Intravenous Push Dose of Low Dose Ketamine to Short Infusion of Low Dose Ketamine for Treatment of Moderate to Severe Pain in the Emergency Department: A Prospective, Randomized, Double-Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our recent research comparing the efficacy of intravenous ketamine to morphine has shown
      ketamine to provide equivalent relief of moderate to severe acute pain in emergency medicine
      patients. Secondary analysis of the research has also revealed ketamine to have
      statistically more side effects. The investigators believe that increasing the time of
      administration of the ketamine, from a push injection to a drip infusion, will minimize the
      side effects experienced by recipients of ketamine.

      During our &quot;Ketamorph&quot; trial the investigators saw that 70% of patients receiving ketamine
      experienced a known side effect of the medication, compared to 51% of the morphine group.
      The most common side effect was dizziness (22 of 45 pts), Feeling of Unreality (12 of 45),
      Mood Changes (6 of 45). During this trial there we NO adverse effects that we beyond the
      expected side effects profile of either medication and none of the participants required
      intervention as a result of the study medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketamine is a noncompetitive N-methyl D-aspartate (NMDA) receptor antagonist that blocks the
      release of excitatory neurotransmitter glutamate and provides anesthesia, amnesia and
      analgesia by virtue of decreasing central sensitization and &quot;wind-up&quot; phenomenon. At low
      (sub-dissociative, analgesics) doses of 0.1-0.4 mg/kg either as an adjunct to opioid
      analgesics or as a single agent, ketamine provides good analgesia while preserving airway
      patency, ventilation, and cardiovascular stability. In addition, the low-dose of ketamine
      increases the analgesic potency of opioids thus decreasing their requirements. Several
      recent studies of low-dose ketamine administered together with morphine provided acceptable
      pain relief to 55-60% of patients with minor side effects of dizziness, nausea and feeling
      of unreality. More recently the investigators conducted a research comparing Low-Dose
      Ketamine to Morphine for Moderate to Severe Pain in the Emergency Department with respect
      its analgesic efficacy and safety. Results demonstrated similar pain relief at 30 min
      between 2 groups. However, 70% of patients in ketamine group had minor side effects at 5 min
      and 35% of patients at 30 min, as compared to 51% at 5 min. and 31% at 15 min. in the
      morphine group. The most common side effects reported by ketamine patients were dizziness,
      nausea, feeling of unreality, and mood changes.

      Based on the mentioned data, we hypothesized that low-dose ketamine given as a short
      infusion over 15 min will provide similar analgesic efficacy as an intravenous push-dose but
      with much less side effects. There are several research papers that support our hypothesis.

      A prospective, randomized trial compared two analgesic regimens, morphine with ketamine (K
      group) or morphine with placebo (P group) for severe acute pain in 73 trauma patients with a
      visual analog scale (VAS) score of at least 60/100. Morphine was administered at 0.1mg/kg
      and patients in the K group received 0.2 mg/kg of intravenous ketamine over 10 minutes, and
      the patients in the P group received isotonic sodium chloride solution. The results showed
      comparable change in VAS score at 30 minutes (34 mm (K) vs. 39 mm (P)) but reduced morphine
      consumption in the ketamine group (0.14 mg/kg (K) vs 0.2 mg/kg (P)).

      A double-blind trial of 40 adult patients with acute musculoskeletal trauma compared a
      low-dose ketamine by subcutaneous infusion (0.1 mg/kg/h) with intermittent morphine (0.1
      mg/kg IV every 4 hours ) and demonstrated better pain relief, less sedation and less nausea
      and vomiting with ketamine infusion than with intermittent morphine. In addition, none of
      the patients in ketamine group required supplementary analgesia.

      A prospective case series of 20 unselected adult ED patients with acute pain that evaluated
      analgesic feasibility of low-dose ketamine infusion was conducted in an urban public
      hospital over a course of 5 months. Patients received 15mg of intravenous push dose ketamine
      that was followed by continuous ketamine infusion at 20mg per hour for one hour. Optional
      morphine (4 mg) was offered at 20, 40 and 60 minutes. Pain intensity was assessed at regular
      intervals for 2 hours using a 10-point verbal numerical rating scale (NRS), along with vital
      signs and levels of sedation. Results showed that fifteen patients reported clinically
      significant pain relief at 60 minutes and 13 at 120 minutes; and eighteen patients reported
      mild or modest side effects including dizziness, fatigue and headache.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>30 minutes</time_frame>
    <description>Quantification and comparison of adverse effects of sub-dissociative dose Ketamine given by intravenous push or infusion in the treatment of acute severe pain in patients of the ED.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Relief</measure>
    <time_frame>30 minutes</time_frame>
    <description>Pain Relief at 30 minutes post administration of medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>IV Push Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketamine medication given via IV Push. IV Push is the intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Drip Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketamine medication given via IV Drip. IV Drip is the intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>IV Push or or IV Drip</description>
    <arm_group_label>IV Push Group</arm_group_label>
    <arm_group_label>IV Drip Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Emergency Medicine patients

          -  Adult patients (18-65 years of age)

          -  Moderate to severe pain (Numeric Pain Rating Score =5).

          -  Patients must be awake, alert and oriented to time, place and person.

          -  Patients must be able to demonstrate understanding of the informed consent, and also
             able to verbalize how much pain they are having on the 10 point Numeric Rating Pain
             Scale, and the nature of the side effects they may be experiencing from the IV
             analgesia

        Exclusion Criteria:

          -  Patients with cognitive deficits that are not able to demonstrate understanding as
             described above.

          -  Patient's reported weight of less than 45kg or more than 115kg.

          -  Patients with altered mental status, alcohol intoxication, eye trauma.

          -  Patients with hemodynamic instability (Systolic Blood pressure &lt;90), and malignant
             hypertension.

          -  allergy to ketamine

          -  Pregnancy or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Motov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Marshall, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Fromm, MD</last_name>
    <role>Study Director</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>1. Abdullah M. Ketamine. A new look at an old drug. M ABDULLAH. anaesthetics.ukzn.ac.za/.../Ketamine_a_new_look_at_an_old_drug_...(accessed on 12/21/11)</citation>
  </reference>
  <reference>
    <citation>Javery KB, Ussery TW, Steger HG, Colclough GW. Comparison of morphine and morphine with ketamine for postoperative analgesia. Can J Anaesth. 1996 Mar;43(3):212-5.</citation>
    <PMID>8829857</PMID>
  </reference>
  <reference>
    <citation>Lester L, Braude DA, Niles C, Crandall CS. Low-dose ketamine for analgesia in the ED: a retrospective case series. Am J Emerg Med. 2010 Sep;28(7):820-7. doi: 10.1016/j.ajem.2009.07.023. Epub 2010 Apr 2.</citation>
    <PMID>20837262</PMID>
  </reference>
  <reference>
    <citation>Richards JR, Rockford RE. Low-dose ketamine analgesia: patient and physician experience in the ED. Am J Emerg Med. 2013 Feb;31(2):390-4. doi: 10.1016/j.ajem.2012.07.027. Epub 2012 Oct 4.</citation>
    <PMID>23041484</PMID>
  </reference>
  <reference>
    <citation>Gurnani A, Sharma PK, Rautela RS, Bhattacharya A. Analgesia for acute musculoskeletal trauma: low-dose subcutaneous infusion of ketamine. Anaesth Intensive Care. 1996 Feb;24(1):32-6.</citation>
    <PMID>8669651</PMID>
  </reference>
  <reference>
    <citation>Galinski M, Dolveck F, Combes X, Limoges V, Sma√Øl N, Pommier V, Templier F, Catineau J, Lapostolle F, Adnet F. Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emerg Med. 2007 May;25(4):385-90.</citation>
    <PMID>17499654</PMID>
  </reference>
  <reference>
    <citation>Terence L. Ahern, Andrew A. Herring, Bradley W. Frazee. Alameda County Medical Center - Highland Hospital, Oakland, CA Safety And Efficacy Of Low-dose Ketamine Infusion For Emergency Department Patients With Acute Severe Pain</citation>
  </reference>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 6, 2016</lastchanged_date>
  <firstreceived_date>February 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Analgesia</keyword>
  <keyword>ketamine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
